Option Care Health, Inc. (NASDAQ:OPCH) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Option Care Health, Inc. (NASDAQ:OPCH) have received an average recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $30.5385.

Several research analysts have recently issued reports on OPCH shares. Zacks Research lowered Option Care Health from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th. Morgan Stanley set a $28.00 target price on Option Care Health in a research report on Wednesday, May 6th. Bank of America lowered Option Care Health from a “buy” rating to a “neutral” rating and set a $22.00 target price for the company. in a research report on Friday, May 1st. Truist Financial set a $30.00 target price on Option Care Health in a research report on Friday, May 1st. Finally, The Goldman Sachs Group started coverage on Option Care Health in a research report on Monday, June 8th. They issued a “neutral” rating and a $22.00 target price for the company.

Option Care Health Stock Up 1.6%

Shares of NASDAQ OPCH opened at $21.82 on Friday. The company has a current ratio of 1.64, a quick ratio of 1.07 and a debt-to-equity ratio of 0.85. Option Care Health has a 12 month low of $18.01 and a 12 month high of $36.80. The firm has a market capitalization of $3.43 billion, a PE ratio of 16.91, a price-to-earnings-growth ratio of 1.19 and a beta of 0.67. The firm has a fifty day simple moving average of $22.38 and a two-hundred day simple moving average of $28.65.

Option Care Health (NASDAQ:OPCH) last issued its quarterly earnings data on Thursday, April 30th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.37 by $0.03. Option Care Health had a net margin of 3.64% and a return on equity of 18.17%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.39 billion. During the same period in the prior year, the business earned $0.40 EPS. The company’s revenue for the quarter was up 1.3% on a year-over-year basis. Option Care Health has set its FY 2026 guidance at 1.820-1.920 EPS. Equities analysts expect that Option Care Health will post 1.64 earnings per share for the current year.

Insider Buying and Selling

In other Option Care Health news, Director Timothy P. Sullivan purchased 24,154 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was bought at an average cost of $20.69 per share, for a total transaction of $499,746.26. Following the purchase, the director directly owned 73,383 shares in the company, valued at $1,518,294.27. The trade was a 49.06% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO John Charles Rademacher purchased 12,500 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was acquired at an average price of $21.18 per share, with a total value of $264,750.00. Following the completion of the purchase, the chief executive officer owned 695,152 shares in the company, valued at $14,723,319.36. This represents a 1.83% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 73,264 shares of company stock worth $1,548,316 in the last three months. 1.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Durable Capital Partners LP increased its position in Option Care Health by 134.2% during the 2nd quarter. Durable Capital Partners LP now owns 8,237,577 shares of the company’s stock valued at $267,557,000 after buying an additional 4,720,988 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its position in Option Care Health by 12.1% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 6,958,800 shares of the company’s stock valued at $221,707,000 after buying an additional 752,058 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in Option Care Health by 6.2% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,248,425 shares of the company’s stock valued at $135,355,000 after buying an additional 247,118 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Option Care Health by 0.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,876,856 shares of the company’s stock valued at $104,368,000 after buying an additional 36,208 shares in the last quarter. Finally, Southpoint Capital Advisors LP increased its position in Option Care Health by 20.0% during the 1st quarter. Southpoint Capital Advisors LP now owns 3,600,000 shares of the company’s stock valued at $96,912,000 after buying an additional 600,000 shares in the last quarter. Institutional investors own 98.05% of the company’s stock.

Option Care Health Company Profile

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.